
    
      The objective of this study is to assess the safety of a single-tablet dose of Combo
      Formulation for the treatment of moderate to severe migraines, with an optional second dose
      at least 2 hours following the first dose, if needed. Combo Formulation will be administered
      on average at least twice per month for 12 months.
    
  